|
Fri, 06/22/2018 - 19:09 |
Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA (sitagliptin) |
Merck |
|
Fri, 06/22/2018 - 01:10 |
FDA permits marketing of first catheter-based systems used to create vascular access for hemodialysis patients |
FDA |
|
Tue, 06/19/2018 - 15:01 |
ECMC and the Seneca Diabetes Foundation Announce Important Partnership |
Erie County Med... |
|
Mon, 06/18/2018 - 11:57 |
Late-Breaking Data to be Presented from the Comparative Trials with Sitagliptin (CompoSIT) Program on the Continuation of JANUVIA (sitagliptin) Treatment Among Patients Initiating Insulin Therapy |
Merck |
|
Fri, 06/15/2018 - 18:20 |
Health Professionals Demand Protections as CarePoint Health proposes Outsourcing and Closure of Services for Hudson County Hospitals |
Health Professi... |
|
Fri, 06/15/2018 - 11:15 |
National Kidney Foundation Statement on the California Ballot Initiative, The Fair Pricing for Dialysis Act |
National Kidney... |
|
Tue, 06/12/2018 - 12:19 |
Mission moment: putting fears to rest |
BlueCross BlueS... |
|
Mon, 06/11/2018 - 21:13 |
NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in Acute Dialysis Quality Initiative Recommendations |
BioMerieux |
|
Mon, 06/11/2018 - 19:59 |
UCLA Kidney Transplant Program leads the nation in numbers and vision |
UCLA |
|
Fri, 06/08/2018 - 11:19 |
Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia |
Genentech |
|
Fri, 06/08/2018 - 04:01 |
Featured Data Includes Findings From OBSERVE-4D the Largest Real-World Study to Evaluate the Risk of Lower Extremity Amputation and Hospitalization for Heart Failure |
Johnson and Johnson |
|
Thu, 06/07/2018 - 08:36 |
FDA Approves Genentechs Rituxan (Rituximab) for Pemphigus Vulgaris |
Genentech |
|
Tue, 06/05/2018 - 01:06 |
NKF Applauds CareDx for New Living Donor Policy |
National Kidney... |
|
Mon, 06/04/2018 - 08:27 |
New test can predict diabetic kidney disease before it occurs |
UWA |
|
Fri, 06/01/2018 - 09:35 |
Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma |
BMS |
|
Fri, 06/01/2018 - 04:01 |
Mount Sinai and RenalytixAI Launch Groundbreaking Artificial Intelligence Solution For Improved Kidney Disease Management and Patient Care |
Mount Sinai |
|
Tue, 05/22/2018 - 13:31 |
Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan |
Kyowa Hakko |
|
Tue, 05/22/2018 - 09:35 |
Atlantic Health System and Kindred Break Ground on State-Of-The-Art Atlantic Rehabilitation Institute |
Atlantic Health... |
|
Mon, 05/21/2018 - 04:41 |
ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV |
GlaxoSmithKline |
|
Thu, 05/17/2018 - 09:00 |
LYRICA (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint |
Pfizer |
|
Tue, 05/15/2018 - 10:04 |
Pfizers Biosimilar RETACRIT (epoetin alfa-epbx) Approved by U.S. FDA |
Pfizer |
|
Mon, 05/14/2018 - 11:24 |
National Kidney Foundation Statement on American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs |
National Kidney... |
|
Fri, 05/11/2018 - 06:40 |
National Kidney Foundation Statement on Legislation Passed in Colorado to Provide Paid Leave for Living Organ Donors |
National Kidney... |
|
Wed, 05/09/2018 - 23:40 |
Chugais Anti-IL-31 Receptor A Humanized Monoclonal Antibody nemolizumab, Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online |
Chugai |
|
Wed, 05/09/2018 - 08:40 |
Healthcare Facility Regulation Division Receives Recognition for Coordinating Post-Hurricane Maria Evacuee Medical Services |
DCH Georgia |
